➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for TD-1473

Email this page to a colleague

« Back to Dashboard

What is the drug development status for TD-1473?

TD-1473 is an investigational drug.

There have been 10 clinical trials for TD-1473. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2019.

The most common disease conditions in clinical trials are Inflammatory Bowel Diseases, Ulcer, and Colitis, Ulcerative. The leading clinical trial sponsors are Theravance Biopharma, Theravance Biopharma R & D, Inc., and Mayo Clinic.

There is one US patent protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for TD-1473
Single Dose Bioavailability and Ethnobridging PK Study in Healthy SubjectsTheravance BiopharmaPhase 1
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyTheravance BiopharmaPhase 2/Phase 3
Rifaximin in Patients With Diabetic GastroparesisMayo ClinicPhase 2

See all TD-1473 clinical trials

Clinical Trial Summary for TD-1473

Top disease conditions for TD-1473
Top clinical trial sponsors for TD-1473

See all TD-1473 clinical trials

International Patents for TD-1473

Drugname Country Document Number Estimated Expiration Related US Patent
TD-1473 Australia AU2016267141 2035-05-28 ⤷  Free Forever Trial
TD-1473 Australia AU2020202181 2035-05-28 ⤷  Free Forever Trial
TD-1473 Brazil BR112017025542 2035-05-28 ⤷  Free Forever Trial
TD-1473 Canada CA2983453 2035-05-28 ⤷  Free Forever Trial
TD-1473 Chile CL2017002994 2035-05-28 ⤷  Free Forever Trial
TD-1473 China CN107667108 2035-05-28 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.